EGFR and bone metastasis: With subgroup analyses, there were no differences in median PFS according to the co-mutation status (P = 0.623), pathogenic co-mutation status (P = 0.885), EGFR mutation type (P = 0.214), brain metastasis (P = 0.417), liver metastasis (P = 0.428), bone metastasis (P = 0.334), dose interruption (P = 0.227), dose reduction (P = 0.970), and grade 3/4 AEs (P = 0.464).